Frank Manganella
Corporate Officer/Principal bei NEXIEN BIOPHARMA, INC.
Profil
Frank Manganella is the founder and CEO of CH3 Partners LLC, which was founded in 2015.
He is also the founder of Ch3 Ventures.
Currently, he holds the position of Vice President-Corporate Development at Nexien BioPharma, Inc. since 2018 and the position of Chief Financial Officer & Managing Partner at CRx Bio Holdings LLC since 2017.
In the past, he worked as Managing Director & Head-FICC Sales at Commerzbank AG from 2011 to 2014.
Mr. Manganella received an MBA from Durham University Business School in 2013.
Aktive Positionen von Frank Manganella
| Unternehmen | Position | Beginn |
|---|---|---|
| NEXIEN BIOPHARMA, INC. | Corporate Officer/Principal | 30.10.2018 |
| CH3 Partners LLC | Vorstandsvorsitzender | 01.10.2015 |
CRx Bio Holdings LLC
 CRx Bio Holdings LLC Pharmaceuticals: OtherHealth Technology CRx Bio Holdings LLC engages in the research and development of advanced cannabinoid therapeutic formulations with the objective of enhancing the bioavailability, pharmacokinetics, and pharmacodynamics of cannabinoids. The company was founded by Alex Wasyl and is headquartered in Princeton, NJ. | Finanzdirektor/CFO | 01.11.2017 |
| Ch3 Ventures | Gründer | - |
Ehemalige bekannte Positionen von Frank Manganella
| Unternehmen | Position | Ende |
|---|---|---|
| COMMERZBANK AG | Corporate Officer/Principal | 01.06.2014 |
Ausbildung von Frank Manganella
| Durham University Business School | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| COMMERZBANK AG | Finance |
| NEXIEN BIOPHARMA, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
CRx Bio Holdings LLC
CRx Bio Holdings LLC Pharmaceuticals: OtherHealth Technology CRx Bio Holdings LLC engages in the research and development of advanced cannabinoid therapeutic formulations with the objective of enhancing the bioavailability, pharmacokinetics, and pharmacodynamics of cannabinoids. The company was founded by Alex Wasyl and is headquartered in Princeton, NJ. | Health Technology |
| CH3 Partners LLC | |
| Ch3 Ventures |
